LON:ONC Oncimmune (ONC) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesInsider TradesBuy This Stock About Oncimmune Stock (LON:ONC) 30 days 90 days 365 days Advanced Chart Get Oncimmune alerts:Sign Up Key Stats Today's Range N/A50-Day Range 1.14▼ 8.0152-Week Range N/AVolumeN/AAverage Volume589,365 shsMarket Capitalization£1.29 millionP/E Ratio0.13Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Leeds, the United Kingdom. Read More Receive ONC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncimmune and its competitors with MarketBeat's FREE daily newsletter. Email Address ONC Stock News HeadlinesOncimmune Holdings Faces Administration and Adviser ResignationsMarch 26, 2025 | tipranks.comOncimmune Holdings to Enter Administration and Suspend TradingMarch 17, 2025 | tipranks.comCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just discovered a new way to do it with 10X less money.August 22 at 2:00 AM | Investors Alley (Ad)Oncimmune Share Chat (ONC)February 26, 2025 | lse.co.ukOncimmune Holdings Full Year 2024 Earnings: Misses ExpectationsFebruary 18, 2025 | finance.yahoo.comOncimmune schedules General Meeting for March approvalFebruary 12, 2025 | msn.comOncimmune forecasts 33% revenue growth in 2025 after doubling in 2024February 10, 2025 | lse.co.ukOncimmune Holdings shares tick up as notes new contractsOctober 31, 2024 | lse.co.ukSee More Headlines ONC Stock Analysis - Frequently Asked Questions How were Oncimmune's earnings last quarter? Oncimmune Holdings plc (LON:ONC) issued its quarterly earnings data on Monday, February, 10th. The company reported ($4.72) EPS for the quarter. Oncimmune had a negative trailing twelve-month return on equity of 2,277.74% and a net margin of 581.63%. How do I buy shares of Oncimmune? Shares of ONC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Oncimmune own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oncimmune investors own include B&M European Value Retail (BME), Coats Group (COA), 4D pharma (DDDD), genedrive (GDR), Greencore Group (GNC), Intel (INTC) and IQE (IQE). Company Calendar Last Earnings2/10/2025Today8/22/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:ONC CIKN/A Weboncimmune.com Phone+44-115-8231869FaxN/AEmployees52Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX 8.87 Trailing P/E Ratio0.13 Forward P/E RatioN/A P/E GrowthN/ANet Income£10.79 million Net Margins581.63% Pretax MarginN/A Return on Equity-2,277.74% Return on Assets-26.38% Debt Debt-to-Equity Ratio-412.06 Current Ratio1.14 Quick Ratio0.63 Sales & Book Value Annual Sales£1.86 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow11.96 Book ValueGBX (1.72) per share Price / BookN/AMiscellaneous Outstanding Shares113,304,985Free FloatN/AMarket Cap£1.29 million OptionableNot Optionable Beta1.19 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (LON:ONC) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredUS attacks China, September 30?The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...Stansberry Research | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncimmune Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.